ストックスクリーナーアプリを入手
22.05
1.17%
-0.26
アフターアワーズ：
22.05
Apellis Pharmaceuticals Inc (APLS) 最新ニュース
(APLS) Risk Channels and Responsive Allocation - Stock Traders Daily
Apellis Pharmaceuticals (APLS) Valuation Check After Recent S&P 1000 Index Inclusion - Yahoo Finance
Apellis Pharmaceuticals, Inc. $APLS Shares Sold by Savant Capital LLC - MarketBeat
ING Groep NV Acquires 866,200 Shares of Apellis Pharmaceuticals, Inc. $APLS - MarketBeat
Apellis Pharmaceuticals to Host Conference Call on February 24, 2026, to Discuss Fourth Quarter and Full Year 2025 Financial Results - The Manila Times
Market Overview: Will Apellis Pharmaceuticals Inc outperform the market in YEARWeekly Trade Recap & Free Risk Controlled Daily Trade Plans - baoquankhu1.vn
Broad S&P Index Inclusion Might Change The Case For Investing In Apellis Pharmaceuticals (APLS) - simplywall.st
A Look At Apellis Pharmaceuticals (APLS) Valuation After Recent S&P Index Additions - Sahm
5 Drug/Biotech Stocks Likely to Outperform Q4 Earnings Estimates - TradingView
How Empaveli’s Rapid Uptake and Q4 2025 Revenue Momentum Will Impact Apellis Pharmaceuticals (APLS) Investors - Sahm
(APLS) Movement as an Input in Quant Signal Sets - Stock Traders Daily
BofA Upgrades Apellis (APLS) to Buy Citing Rapid Empaveli Adoption and Underappreciated Kidney Disease Market Potential - Finviz
Will Apellis Pharmaceuticals Inc. benefit from geopolitical trendsShort Setup & Reliable Intraday Trade Alerts - mfd.ru
Apellis Pharmaceuticals (NASDAQ:APLS) Upgraded to Hold at Barclays - MarketBeat
Apellis Pharmaceuticals (APLS) Surges 5.8%: Is This an Indication of Further Gains? - Yahoo Finance
J. Safra Sarasin Holding AG Sells 45,184 Shares of Apellis Pharmaceuticals, Inc. $APLS - MarketBeat
Apellis Pharmaceuticals (NASDAQ:APLS) Stock Price Up 7.5%Still a Buy? - MarketBeat
Apellis Pharmaceuticals (APLS) Receives Equal-Weight Rating from Barclays | APLS Stock News - GuruFocus
This Oklo Analyst Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Wednesday - Benzinga
Apellis Pharmaceuticals (NASDAQ:APLS) Coverage Initiated at Barclays - MarketBeat
Apellis Pharmaceuticals, Inc. (APLS) Stock Analysis: Exploring A 56.89% Upside Potential - DirectorsTalk Interviews
TTM Technologies, Dutch Bros to join S&P 400 Index; Amneal, Apellis to be part of S&P SmallCap 600 (CIVI:NYSE) - Seeking Alpha
TTM Technologies, Dutch Bros, Advanced Energy Industries, and American Healthcare REIT Set to Join S&P MidCap 400; Others to Join S&P SmallCap 600 - Benzinga
Analysts Offer Insights on Healthcare Companies: Apellis Pharmaceuticals (APLS), Ascendis Pharma (ASND) and Abivax SA Sponsored ADR (ABVX) - The Globe and Mail
A Look At Apellis Pharmaceuticals (APLS) Valuation As GAAP Profitability And Syfovre Commercialization Gain Traction - Yahoo Finance
Apellis Turns GAAP Profitable As Syfovre Sales Shift Story To Execution - Sahm
Apellis Pharmaceuticals, Inc. $APLS Shares Bought by EFG Asset Management North America Corp. - MarketBeat
Value Recap: Is BAFN a strong growth stockGap Up & Reliable Breakout Stock Forecasts - baoquankhu1.vn
Buybacks Report: Will Apellis Pharmaceuticals Inc. benefit from geopolitical trendsQuarterly Portfolio Summary & High Accuracy Swing Trade Signals - baoquankhu1.vn
Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Receives Average Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Apellis upgraded at BofA on launch trajectory for kidney disease therapy - MSN
Apellis, Olema, Exicure, Immunovant, LivePerson Insider Shake-Up - TipRanks
Apellis Pharma CEO Francois sells $592k in shares By Investing.com - Investing.com Canada
Caroline Baumal Sells 2,797 Shares of Apellis Pharmaceuticals (NASDAQ:APLS) Stock - MarketBeat
Apellis Pharmaceuticals (NASDAQ:APLS) General Counsel David Watson Sells 7,832 Shares - MarketBeat
Insider Selling: Apellis Pharmaceuticals (NASDAQ:APLS) CAO Sells 2,064 Shares of Stock - MarketBeat
Timothy Eugene Sullivan Sells 10,287 Shares of Apellis Pharmaceuticals (NASDAQ:APLS) Stock - MarketBeat
Apellis stock surges after Sobi $300 million royalty deal - MSN
Aug Retail: Does Apellis Pharmaceuticals Inc stock have upside surprise potentialSell Signal & Real-Time Chart Pattern Alerts - baoquankhu1.vn
Apellis Pharmaceuticals (NASDAQ:APLS) Fits the 'Affordable Growth' Investment Strategy - ChartMill
Nicholson nur, Apellis Pharmaceuticals CTO, sells $43k in APLS stock - Investing.com Nigeria
Apellis Pharma CMO Baumal sells $37k in shares By Investing.com - Investing.com India
Nicholson nur, Apellis Pharmaceuticals CTO, sells $43k in APLS stock By Investing.com - Investing.com South Africa
Apellis Pharma VP Chopas sells $14k in shares By Investing.com - Investing.com Canada
Insider Selling: Apellis Pharmaceuticals (NASDAQ:APLS) CEO Sells 8,182 Shares of Stock - MarketBeat
Apellis Pharmaceuticals (NASDAQ:APLS) Insider Sells $26,399.86 in Stock - MarketBeat
Insider Selling: Apellis Pharmaceuticals (NASDAQ:APLS) Insider Sells 909 Shares of Stock - MarketBeat
Insider Selling: Apellis Pharmaceuticals (NASDAQ:APLS) Insider Sells 1,882 Shares of Stock - MarketBeat
Insider Selling: Apellis Pharmaceuticals (NASDAQ:APLS) General Counsel Sells 2,475 Shares of Stock - MarketBeat
Insider Selling: Apellis Pharmaceuticals (NASDAQ:APLS) CFO Sells 2,892 Shares of Stock - MarketBeat
Apellis Pharmaceuticals' Empaveli Approved, Projected $508 Million Sales by 2033 - Intellectia AI
Bank of America Upgrades Apellis Pharmaceuticals (APLS) Amid Suc - GuruFocus
Bank of America Upgrades Apellis Pharmaceuticals to Buy, Highlights Strong Empaveli Launch - intellectia.ai
Why Is Apellis Pharma Stock Gaining Wednesday?Apellis Pharmaceuticals (NASDAQ:APLS) - Benzinga
Apellis Valuation Ignores Empaveli Potential, Says Analyst - Sahm
1.24%
0.19%
大文字化:
|
ボリューム (24 時間):